Company Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases.
Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease.
The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020.
Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
| Country | United States |
| Founded | 2013 |
| IPO Date | Jun 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 254 |
| CEO | Grant Pickering |
Contact Details
Address: 825 Industrial Road, Suite 300 San Carlos, California 94070 United States | |
| Phone | 650 837 0111 |
| Website | vaxcyte.com |
Stock Details
| Ticker Symbol | PCVX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001649094 |
| CUSIP Number | 92243G108 |
| ISIN Number | US92243G1085 |
| Employer ID | 46-4233385 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Grant Pickering | Chief Executive Officer |
| Andrew Guggenhime | Chief Financial Officer |
| James Wassil | Chief Operating Officer |
| Janet Graesser | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 1, 2024 | 144 | Filing |
| Oct 1, 2024 | 144 | Filing |
| Oct 1, 2024 | 144 | Filing |
| Sep 18, 2024 | 144 | Filing |
| Sep 17, 2024 | 144 | Filing |
| Sep 16, 2024 | 144 | Filing |
| Sep 6, 2024 | 8-K | Current Report |
| Sep 5, 2024 | 424B5 | Filing |
| Sep 3, 2024 | 144 | Filing |
| Sep 3, 2024 | 144 | Filing |